{"id":731062,"date":"2025-02-11T17:44:01","date_gmt":"2025-02-11T17:44:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=731062"},"modified":"2025-02-11T17:44:01","modified_gmt":"2025-02-11T17:44:01","slug":"alpha1-antitrypsin-deficiency-clinical-trials-and-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/alpha1-antitrypsin-deficiency-clinical-trials-and-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies-by-delveinsight_731062.html","title":{"rendered":"Alpha-1 Antitrypsin Deficiency Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2025\/02\/1739280821.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Alpha-1 Antitrypsin Deficiency Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2025\/02\/1739280821.jpg\" alt=\"Alpha-1 Antitrypsin Deficiency Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, &ldquo;<strong>Alpha 1 Antitrypsin Deficiency Pipeline Insight<\/strong>&rdquo; report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Alpha 1 Antitrypsin Deficiency pipeline landscape. It covers the Alpha 1 Antitrypsin Deficiency pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Alpha 1 Antitrypsin Deficiency therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Alpha 1 Antitrypsin Deficiency pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Stay ahead with the latest insights! Download DelveInsight&rsquo;s comprehensive Alpha 1 Antitrypsin Deficiency Pipeline Report to explore emerging therapies, key Alpha 1 Antitrypsin Deficiency Companies, and future Alpha 1 Antitrypsin Deficiency treatment landscapes @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/alpha-1-antitrypsin-deficiency-aatd-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Alpha 1 Antitrypsin Deficiency Pipeline Outlook Report<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Alpha 1 Antitrypsin Deficiency Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong><em>In February 2025:- Grifols Therapeutics Inc.:-<\/em><\/strong> The purpose of this study is to evaluate the safety and tolerability of 72 milligrams per kilogram (mg\/kg) and 180 mg\/kg Alpha-1 15%, administered as a single-dose subcutaneous (SC) infusion and subsequently as weekly SC infusions over 8 weeks in participants with Alpha1-Antitrypsin Deficiency (AATD).<\/li>\n<li><strong><em>In January 2025:- Takeda<\/em><\/strong>:- The liver produces a protein called alpha-1 antitrypsin (AAT). AAT is normally released into the bloodstream. In some people, the liver makes an abnormal version of the AAT protein, called Z-AAT. Making an abnormal version of the AAT protein can result in liver disease as Z-AAT builds up in liver cells, which leads to liver problems such as liver scarring (fibrosis), continuing liver damage (cirrhosis), and eventually endstage liver disease.<\/li>\n<li><strong><em>In January 2025:- Korro Bio Inc.:-<\/em><\/strong> The purpose of this first-in human (FIH) study is to assess the safety, tolerability, and pharmacokinetics (PK) of single and multiple doses of KRRO-110 in both healthy adult participants and in clinically stable patients with Alpha-1 antitrypsin deficiency (AATD).<\/li>\n<li><strong><em>In January 2025:- Arrowhead Pharmaceuticals:<\/em><\/strong>&#8211; The purpose of AROAAT2001 (SEQUOIA) is to evaluate the safety, efficacy and tolerability of multiple doses of the investigational product, Fazirsiran Injection, administered subcutaneously to participants with alpha-1 antitrypsin deficiency (AATD).<\/li>\n<li><strong><em>In January 2025:- Kamada Ltd:-<\/em><\/strong> The goal of this clinical trial is to learn if AAT for inhalation, at a dose of 80 mg\/day can slow the progression of lung disease in people who have lung disease caused by severe genetic deficiency in Alpha 1 Antitrypsin (AATD).<\/li>\n<li>DelveInsight&rsquo;s Alpha 1 Antitrypsin Deficiency pipeline report depicts a robust space with 12+ active players working to develop 12+ pipeline therapies for Alpha 1 Antitrypsin Deficiency treatment.<\/li>\n<li>The leading Alpha 1 Antitrypsin Deficiency Companies such as <strong><em>Octapharma, Dicerna Pharmaceuticals, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Vertex Pharmaceuticals, AstraZeneca, Kamada Ltd<\/em><\/strong> and others.<\/li>\n<li>Promising Alpha-1 Antitrypsin Deficiency Pipeline Therapies such as <strong><em>Fazirsiran Injection, Aerosolized, Recombinant Alpha 1-Antitrypsin, INBRX-101\/rhAAT-Fc, ADVM-043<\/em><\/strong>, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover how the Alpha 1 Antitrypsin Deficiency treatment paradigm is evolving. Access DelveInsight&rsquo;s in-depth Alpha 1 Antitrypsin Deficiency Pipeline Analysis for a closer look at promising breakthroughs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/alpha-1-antitrypsin-deficiency-aatd-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Alpha 1 Antitrypsin Deficiency Clinical Trials and Studies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Alpha 1 Antitrypsin Deficiency Emerging Drugs Profile<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>ARO AAT: Arrowhead Pharmaceuticals<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">ARO AAT is a second generation, N-Acetylgalactosamine (GalNAc) based, subcutaneously administered RNA interference based therapeutic. ARO-AAT is designed to knock down the hepatic production of the mutant alpha-1 antitrypsin (Z-AAT) protein, the cause of progressive liver disease in AATD patients. In June 2019, the US FDA has granted Fast Track designation to ARO-AAT. ARO-AAT is in Phase III clinical studies for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD).<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>ALN-AAT02: Alnylam Pharmaceuticals<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">ALN AAT02 is a subcutaneously administered RNAi therapeutic that targets alpha-1 antitrypsin (AAT). ALN-AAT02 is based on the Alnylam&#8217;s enhanced stabilization chemistry plus (ESC+)-GalNAc-conjugate technology, which enables subsequent subcutaneous dosing with increased selectivity and a wide therapeutic index. The drug is currently in Phase I\/II clinical development for the treatment of ZZ Type AAT Deficiency Liver Disease.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>The Alpha 1 Antitrypsin Deficiency pipeline report provides insights into <\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report provides detailed insights about companies that are developing therapies for the treatment of Alpha 1 Antitrypsin Deficiency with aggregate therapies developed by each company for the same.<\/li>\n<li>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alpha 1 Antitrypsin Deficiency Treatment.<\/li>\n<li>Alpha 1 Antitrypsin Deficiency Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>Alpha 1 Antitrypsin Deficiency Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alpha 1 Antitrypsin Deficiency market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a detailed analysis of the latest innovations in the Alpha 1 Antitrypsin Deficiency pipeline. Explore DelveInsight&rsquo;s expert-driven report today! @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/alpha-1-antitrypsin-deficiency-aatd-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Alpha 1 Antitrypsin Deficiency Unmet Needs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Alpha 1 Antitrypsin Deficiency Companies<\/strong><\/p>\n<p style=\"text-align: justify;\">Octapharma, Dicerna Pharmaceuticals, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Vertex Pharmaceuticals, AstraZeneca, Kamada Ltd and others.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Alpha 1 Antitrypsin Deficiency pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Intra-articular<\/li>\n<li>Intraocular<\/li>\n<li>Intrathecal<\/li>\n<li>Intravenous<\/li>\n<li>Ophthalmic<\/li>\n<li>Oral<\/li>\n<li>Parenteral<\/li>\n<li>Subcutaneous<\/li>\n<li>Topical<\/li>\n<li>Transdermal<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Alpha 1 Antitrypsin Deficiency Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Oligonucleotide<\/li>\n<li>Peptide<\/li>\n<li>Small molecule<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download DelveInsight&rsquo;s latest report to gain strategic insights into upcoming Alpha 1 Antitrypsin Deficiency Therapies and key Alpha 1 Antitrypsin Deficiency Developments @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/alpha-1-antitrypsin-deficiency-aatd-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Alpha 1 Antitrypsin Deficiency Market Drivers and Barriers, and Future Perspectives<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Alpha 1 Antitrypsin Deficiency Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>Alpha 1 Antitrypsin Deficiency Companies-<strong><em> Octapharma, Dicerna Pharmaceuticals, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Vertex Pharmaceuticals, AstraZeneca, Kamada Ltd and others.<\/em><\/strong><\/li>\n<li>Alpha-1 Antitrypsin Deficiency Pipeline Therapies<strong><em>&#8211; Fazirsiran Injection, Aerosolized, Recombinant Alpha 1-Antitrypsin, INBRX-101\/rhAAT-Fc, ADVM-043, and others. <\/em><\/strong><\/li>\n<li>Alpha 1 Antitrypsin Deficiency Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>Alpha 1 Antitrypsin Deficiency Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Which companies are leading the race in Alpha 1 Antitrypsin Deficiency drug development? Find out in DelveInsight&rsquo;s exclusive Alpha 1 Antitrypsin Deficiency Pipeline Report&mdash;access it now! @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/alpha-1-antitrypsin-deficiency-aatd-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Alpha 1 Antitrypsin Deficiency Emerging Drugs and Major Companies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>Introduction<\/li>\n<li>Alpha-1 Antitrypsin Deficiency Executive Summary<\/li>\n<li>Alpha-1 Antitrypsin Deficiency: Overview<\/li>\n<li>Alpha-1 Antitrypsin Deficiency Pipeline Therapeutics<\/li>\n<li>Alpha-1 Antitrypsin Deficiency Pipeline Therapeutic Assessment<\/li>\n<li>Alpha-1 Antitrypsin Deficiency&ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>ARO AAT: Arrowhead Pharmaceuticals<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>Drug Name: Company Name<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Early Stage Products (Phase I\/II)<\/li>\n<li>ALN-AAT02: Alnylam Pharmaceuticals<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Preclinical and Discovery Stage Products<\/li>\n<li>Drug Name: Company Name<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Inactive Products<\/li>\n<li>Alpha-1 Antitrypsin Deficiency Key Companies<\/li>\n<li>Alpha-1 Antitrypsin Deficiency Key Products<\/li>\n<li>Alpha-1 Antitrypsin Deficiency- Unmet Needs<\/li>\n<li>Alpha-1 Antitrypsin Deficiency- Market Drivers and Barriers<\/li>\n<li>Alpha-1 Antitrypsin Deficiency- Future Perspectives and Conclusion<\/li>\n<li>Alpha-1 Antitrypsin Deficiency Analyst Views<\/li>\n<li>Alpha-1 Antitrypsin Deficiency Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=alpha1-antitrypsin-deficiency-clinical-trials-and-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/surgical-lasers-market\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/surgical-lasers-market<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=alpha1-antitrypsin-deficiency-clinical-trials-and-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s, &ldquo;Alpha 1 Antitrypsin Deficiency Pipeline Insight&rdquo; report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Alpha 1 Antitrypsin Deficiency pipeline landscape. It covers the Alpha 1 Antitrypsin Deficiency pipeline drug profiles, including clinical and nonclinical stage &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/alpha1-antitrypsin-deficiency-clinical-trials-and-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies-by-delveinsight_731062.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406],"tags":[],"class_list":["post-731062","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/731062","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=731062"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/731062\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=731062"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=731062"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=731062"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}